CA2650311A1 - Improved treatment of cystic fibrosis - Google Patents

Improved treatment of cystic fibrosis Download PDF

Info

Publication number
CA2650311A1
CA2650311A1 CA002650311A CA2650311A CA2650311A1 CA 2650311 A1 CA2650311 A1 CA 2650311A1 CA 002650311 A CA002650311 A CA 002650311A CA 2650311 A CA2650311 A CA 2650311A CA 2650311 A1 CA2650311 A1 CA 2650311A1
Authority
CA
Canada
Prior art keywords
deoxynojirimycin
group
use according
carbon atoms
gba2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002650311A
Other languages
English (en)
French (fr)
Inventor
Johannes Maria Franciscus Gerardus Aerts
Rolf Gabriel Boot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academisch Medisch Centrum
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2650311A1 publication Critical patent/CA2650311A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
CA002650311A 2006-04-24 2007-04-24 Improved treatment of cystic fibrosis Abandoned CA2650311A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79408806P 2006-04-24 2006-04-24
US60/794,088 2006-04-24
PCT/NL2007/050177 WO2007123403A1 (en) 2006-04-24 2007-04-24 Improved treatment of cystic fibrosis

Publications (1)

Publication Number Publication Date
CA2650311A1 true CA2650311A1 (en) 2007-11-01

Family

ID=38283020

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002650311A Abandoned CA2650311A1 (en) 2006-04-24 2007-04-24 Improved treatment of cystic fibrosis

Country Status (10)

Country Link
US (1) US8410081B2 (https=)
EP (1) EP2010551B1 (https=)
JP (1) JP2009538276A (https=)
CN (1) CN101479288B (https=)
AT (1) ATE479696T1 (https=)
AU (1) AU2007241622A1 (https=)
BR (1) BRPI0710883A2 (https=)
CA (1) CA2650311A1 (https=)
DE (1) DE602007008870D1 (https=)
WO (1) WO2007123403A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0712494D0 (en) * 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
EP2398321B1 (en) 2009-02-23 2015-11-25 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
EP2400843B1 (en) * 2009-02-24 2015-11-11 United Therapeutics Corporation Iminosugars and methods of treating arenaviral infections
ES2524361T3 (es) * 2009-06-12 2014-12-05 United Therapeutics Corporation Iminoazúcares para su uso en el tratamiento de enfermedades por bunyavirus y togavirus
CA2772813A1 (en) * 2009-09-04 2011-03-10 The Chancellor, Masters And Scholars Of The University Of Oxford Iminosugars and methods of treating filoviral diseases
JP5653438B2 (ja) * 2009-09-04 2015-01-14 ユナイテッド セラピューティクス コーポレイション オルトミクソウイルス感染の治療方法
CA2772807A1 (en) * 2009-09-04 2011-03-10 The Chancellor, Masters And Scholars Of The University Of Oxford Methods of treating poxviral infections
GB201000499D0 (en) 2010-01-13 2010-03-03 Fleet George W J Treatment of cystic fibrosis
WO2011095772A2 (en) 2010-02-04 2011-08-11 Summit Corporation Plc Novel iminosugar therapeutics
GB201006434D0 (en) 2010-04-19 2010-06-02 Summit Corp Plc Novel iminosugar combinations
LT2753346T (lt) 2011-09-07 2020-08-10 Mount Sinai School Of Medicine Ceramidazė ir ląstelių diferenciacija
ES2897825T3 (es) * 2012-06-01 2022-03-02 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
EP2929346A1 (en) * 2012-12-05 2015-10-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Diagnosis of cystic fibrosis
PT2968479T (pt) 2013-03-14 2019-08-07 Icahn School Med Mount Sinai Composições terapêuticas de ceramidase ácida e métodos de fabrico e utilização
EP3442514B1 (en) 2016-04-11 2021-06-16 Spedding Research Solutions Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units
PL3630725T3 (pl) 2017-06-01 2026-03-23 Idorsia Pharmaceuticals Ltd Postać krystaliczna n-butylodeoksygalaktonojirymycyny
KR20230169989A (ko) * 2021-03-12 2023-12-18 익셉젠 인크. 단백질 발현을 위한 시스템 및 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE322900T1 (de) 1996-07-15 2006-04-15 Macrozyme Dnm B V Deoxynojirimycin derivate und ihre verwendung als glukosesylceramidase-inhibitoren
AU5799500A (en) * 1999-06-29 2001-01-22 Mcgill University Human alpha 1,2-mannosidase
EP1528056A1 (en) * 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
FR2861991B1 (fr) * 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
US20090111812A1 (en) * 2004-06-14 2009-04-30 Musc Foundation For Research Development Methods for treating inflammatory disorders
US20100004156A1 (en) * 2005-07-27 2010-01-07 Shalesh Kaushal Small Compounds That Correct Protein Misfolding and Uses Thereof

Also Published As

Publication number Publication date
EP2010551B1 (en) 2010-09-01
DE602007008870D1 (de) 2010-10-14
CN101479288A (zh) 2009-07-08
US8410081B2 (en) 2013-04-02
US20090186862A1 (en) 2009-07-23
AU2007241622A8 (en) 2008-12-04
AU2007241622A1 (en) 2007-11-01
EP2010551A1 (en) 2009-01-07
WO2007123403A1 (en) 2007-11-01
JP2009538276A (ja) 2009-11-05
CN101479288B (zh) 2012-06-27
ATE479696T1 (de) 2010-09-15
BRPI0710883A2 (pt) 2011-08-09

Similar Documents

Publication Publication Date Title
US8410081B2 (en) Treatment of cystic fibrosis
ES2354976T3 (es) Fosfatasa alcalina placentaria para controlar la diabetes.
US9034847B2 (en) Inhibiting inflammation with milk oligosaccharides
Huynh et al. Oral arginine reduces systemic blood pressure in type 2 diabetes: its potential role in nitric oxide generation
US20110082099A1 (en) Methods and Compositions for the Treatment of Cystic Fibrosis and Related Illnesses
US20020115619A1 (en) Compositions and methods for treatment of cystic fibrosis
US20100286256A1 (en) Compositions and methods for therapy for diseases characterized by defective chloride transport
WO2008150477A2 (en) N-acetyl mannosamine as a therapeutic agent
KR100969634B1 (ko) 글루코사민 또는 글루코사민 유도체를 포함하는 아토피성피부염 치료용 조성물 및 이를 사용하여 아토피성 피부염을치료하는 방법
Yamada et al. Larger improvements in fatigue resistance and mitochondrial function with high‐than with low‐intensity contractions during interval training of mouse skeletal muscle
US6656912B2 (en) Methods to treat α1-antitrypsin deficiency
US7662838B2 (en) Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
Latham et al. Neuroprotective effects of carnitine and its potential application to ameliorate neurotoxicity
BRPI0718522A2 (pt) Uso de um composto, e, método de tratamento para reduzir os níveis de triglicerídeo, colesterol e/ou glicose no sangue
WO2020261230A1 (en) Combination therapy with acetyl-leucine and miglustat
KR101297763B1 (ko) 알츠하이머 병 치료용 의약의 제조를 위한 ｓ-아데노실메티오닌(ｓａｍ) 및 슈퍼옥시드 디스뮤타아제(ｓｏｄ)의 용도
Dayton et al. The Effect of Probenecid, Phenylbutazone, and Their Analogs on the Excretion of L-Ascorbic Acid in Rats1
EP4574142A1 (en) Composition for use in enhancing, boosting, restoring and/or preventing the decline of cognitive functions
TWI742699B (zh) 醫藥組合物用於製備促發炎細胞介素抑制劑及製備治療細胞介素釋放症候群的藥品之用途
JPH0672884A (ja) α‐アミラーゼ阻害剤及びそれを用いた医薬
WO2024036044A1 (en) Compositions and methods for treating and preventing metabolic disorders
Helal et al. Effect Of Some Slimming Drugs On Haematological And Some Vital Signs Of Albino Rats
Linnemann et al. Friedreich
Linnemann et al. Friedreich's ataxia

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130424